Pfizer (PFE) PT Raised to $40.00 at Credit Suisse Group


The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. Credit Suisse Group's price target would indicate a potential upside of 0.58% from the company's current price.



from Biotech News